FDA's biologics chief stresses need for vaccine transmission data

Incorporating disease transmission data into vaccine trial designs could add to their benefit-risk calculus, even though it will likely make vaccines more costly to develop, Peter Marks, chief of the FDA's Center for Biologics Evaluation ...